European Respiratory Society guideline on various aspects of quality in lung cancer care. Issue 2 (16th February 2023)

• Record Type: Journal Article
• Authors: Blum, Torsten Gerriet; Morgan, Rebecca L.; Durieux, Valérie; Chorostowska-Wynimko, Joanna; Baldwin, David R.; Boyd, Jeanette; Faivre-Finn, Corinne; Galateau-Salle, Françoise; Gamarra, Fernando; Grigoriu, Bogdan; Hardavella, Georgia; Hauptmann, Michael; Jakobsen, Erik; Jovanovic, Dragana; Knaut, Paul; Massard, Gilbert; McPhelim, John; Meert, Anne-Pascale; Milroy, Robert; Muhr, Riccardo; Mutti, Luciano; Paesmans, Marianne; Powell, Pippa; Putora, Paul Martin; Rawlinson, Janette; Rich, Anna L.; Rigau, David; de Ruysscher, Dirk; Sculier, Jean-Paul; Schepereel, Arnaud; Subotic, Dragan; Van Schil, Paul; Tonia, Thomy; Williams, Clare; Berghmans, Thierry;
• Is Part Of: European respiratory journal. Volume 61:Issue 2(2023)
• Publication Date: 2023-02-16
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.03201-2021
• Languages: English
• ISSNs: 0903-1936

Abstract

This European Respiratory Society guideline is dedicated to the provision of good quality recommendations in lung cancer care. All the clinical recommendations contained were based on a comprehensive systematic review and evidence syntheses based on eight PICO (Patients, Intervention, Comparison, Outcomes) questions. The evidence was appraised in compliance with the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Evidence profiles and the GRADE Evidence to Decision frameworks were used to summarise results and to make the decision-making process transparent. A multidisciplinary Task Force panel of lung cancer experts formulated and consented the clinical recommendations following thorough discussions of the systematic review results. In particular, we have made recommendations relating to the following quality improvement measures deemed applicable to routine lung cancer care: 1) avoidance of delay in the diagnostic and therapeutic period, 2) integration of multidisciplinary teams and multidisciplinary consultations, 3) implementation of and adherence to lung cancer guidelines, 4) benefit of higher institutional/individual volume and advanced specialisation in lung cancer surgery and other procedures, 5) need for pathological confirmation of lesions in patients with pulmonary lesions and suspected lung cancer, and histological subtyping and molecular characterisation for actionable targets or response to treatment of confirmed lung cancers, 6) added value of early integration of palliative care teams or specialists, 7) advantage of integrating specific quality improvement measures, and 8) benefit of using patient decision tools. These recommendations should be reconsidered and updated, as appropriate, as new evidence becomes available. A multidisciplinary ERS Task Force panel including patient representatives created a clinical practice guideline on good quality in lung cancer care. Implementing the 13 consented recommendations can sustainably improve patient experiences and outcomes. https://bit.ly/3S3NsFQ